Director of the Malaghan Institute of Medical Research Professor Graham Le Gros says that since commercially-available
cancer immunotherapies first appeared on the market less than a decade ago, they have caused a profound change on the
way we target and eradicate cancer. Their potential, he says, lies in harnessing the body’s own natural defences,
offering a more personalised and intimate avenue for cancer treatment – translating to better patient outcomes than
conventional means.
Cancer immunotherapy works by using a patient’s own immune system to identify and destroy cancer cells and tumours.
There are a number of ways the immune system can be recruited in the fight against cancer. For example, the
immunotherapeutic drug Keytruda is a checkpoint blockade, which works by preventing the immune system ‘turning off’,
helping to prolong the attack on a tumour and improve patient outcomes.
“Checkpoint blockades are one piece of the puzzle of getting the immune system to be aware that it's got a cancer and to
react appropriately,” says Prof Le Gros.
“However, this type of treatment runs into trouble if the immune system can’t detect the cancer in the first place. We
still have a lot of work to do to discover how to get the immune system to actually recognise those more 'invisible'
cancers.”
Prof Le Gros says this is where the focus of the Malaghan Institute’s research currently lies – the initiation of the
immune system’s anti-tumour response.
“Much of our research and discovery, such as the Freemasons CAR T-cell Research Programme, looks at how we can more
accurately and reliably train our immune system to identify cancerous cells, and so initiate the anti-tumour response,
using a combination of other therapies such as checkpoint blockades to ensure this response is sustained.”
World Immunology Day on 29 April is a moment, says Prof Le Gros, to reflect on the huge potential of immunotherapy but
also to acknowledge that we are still a way off from finding a reliable ‘cure’.
“Cancer is a hard nut to crack. There’s never going to be just one therapy to cure and remove a cancer from our bodies.
Rather, it’s going to be a portfolio of regimes – sometimes drugs, sometimes surgeries, but certainly immunotherapies –
to identify tumours, remove them and protect the body against what may be left behind.
“We are working towards a future where cancer is treated not by a singular approach, but by a highly sophisticated and
deeply personalised combination of cumulative treatments that effectively identify and eradicate targeted tumours based
on an individual’s specific makeup.”
Image caption: GMP production manager Evelyn Bauer working with CAR T-cells. The ‘good manufacturing practice’ (GMP)
labs were purpose-built by the Malaghan Institute and are more sterile than a hospital’s operating theatre. These labs
will be used to manufacture CAR T-cells for an upcoming cancer immunotherapy clinical trial.
ends